We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

26 hedge funds and large institutions have $1.37M invested in Traws Pharma in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

8% more capital invested

Capital invested by funds: $1.27M → $1.37M (+$96.9K)

0.01% more ownership

Funds ownership: 0.34% → 0.35% (+0.01%)

4% less funds holding

Funds holding: 27 → 26 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
26
Holders Change
-1
Holders Change %
-3.7%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MG
Marex Group
+$101K
2
Morgan Stanley
Morgan Stanley
New York
+$12K
3
Renaissance Technologies
Renaissance Technologies
New York
+$10.3K
4
UBS Group
UBS Group
Switzerland
+$5.16K
5
Millennium Management
Millennium Management
New York
+$2.62K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$58K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$22.2K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$11.5K
4
TSS
Two Sigma Securities
New York
-$7.78K
5
Osaic Holdings
Osaic Holdings
Arizona
-$681
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$528K – – –
BlackRock
2
BlackRock
New York
$186K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$148K +$10.3K +606 +8%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$144K – – –
MG
5
Marex Group
$110K +$101K +5,921 New
Two Sigma Advisers
6
Two Sigma Advisers
New York
$58.1K -$11.5K -675 -18%
State Street
7
State Street
Massachusetts
$39.4K – – –
Two Sigma Investments
8
Two Sigma Investments
New York
$29.4K -$58K -3,412 -68%
Morgan Stanley
9
Morgan Stanley
New York
$28.1K +$12K +704 +88%
Northern Trust
10
Northern Trust
Illinois
$23K – – –
BPA
11
Beacon Pointe Advisors
California
$21.3K +$51 +3 +0.3%
HWA
12
Hillcrest Wealth Advisors
New Jersey
$12.5K – – –
Millennium Management
13
Millennium Management
New York
$11.5K +$2.62K +154 +33%
MA
14
Mutual Advisors
Nebraska
$9.47K – – –
UBS Group
15
UBS Group
Switzerland
$5.71K +$5.16K +303 +10,100%
EDRH
16
Edmond de Rothschild Holding
Switzerland
$4.97K – – –
VWWMG
17
Vermillion & White Wealth Management Group
Pennsylvania
$3.83K +$3.49K +205 New
TRCT
18
Tower Research Capital (TRC)
New York
$2.65K -$153 -9 -6%
Group One Trading
19
Group One Trading
Illinois
$1.2K – – –
Bank of America
20
Bank of America
North Carolina
$506 +$442 +26 +2,600%
Wells Fargo
21
Wells Fargo
California
$120 – – –
TWC
22
TD Waterhouse Canada
Ontario, Canada
$87 – – –
JP Morgan Chase
23
JP Morgan Chase
New York
$27 – – –
CPG
24
Cornerstone Planning Group
New Jersey
$25 – – –
Osaic Holdings
25
Osaic Holdings
Arizona
$3 -$681 -40 Closed
1
2

TRAW Hedge Fund Activity: Q4 2023 in Review

26 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2023, worth a combined $1.37M — up 7.6% from $1.27M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of TRAW and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 7 added.

The largest buyer was Marex Group, opening a new position worth an estimated $101K. The largest seller was Two Sigma Investments, cutting an estimated $58K.

  • 26 institutional investors held Traws Pharma (TRAW) as of Q4 2023, down from 27 in Q3 2023.
  • Funds reported $1.37M of Traws Pharma stock for Q4 2023, up 7.6% quarter-over-quarter.
  • 2 funds opened new Traws Pharma positions in Q4 2023 and 3 closed out, a net change of -1 holder.
  • The largest Traws Pharma buyer in Q4 2023 was Marex Group, an estimated $101K added.
  • The largest Traws Pharma seller in Q4 2023 was Two Sigma Investments, an estimated $58K sold.

Based on aggregated 13F filings for Q4 2023.